(VLA) – Globe Newswire
-
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
-
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
-
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
-
Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F
-
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
-
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
-
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
-
Valneva to Present at the Cowen 43rd Annual Healthcare Conference
-
FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review
-
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
-
Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance
-
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
-
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
-
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate
-
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
-
Valneva Hosts Investor Day in New York City
-
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate
-
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate
-
Valneva to Host Investor Day in New York City
-
Valneva Appoints Dipal Patel as Chief Commercial Officer
-
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
-
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
-
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences
-
Valneva Announces Closing of Upsized €102.9 Million Global Offering
-
Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares
-
Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares
-
Valneva Provides Further Update on its COVID-19 Activities
-
Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
-
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
-
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
-
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001
-
Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine
-
Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
-
Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense
-
Valneva Establishes an At-the-Market (ATM) Program on Nasdaq
-
Valneva Reports H1 2022 Results and Provides Corporate Updates
-
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
-
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine
-
European Commission Approves Purchase Agreement Amendment for Valneva’s Inactivated COVID-19 Vaccine
-
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
-
Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members
-
Valneva and Pfizer Announce Closing of Equity Investment
-
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe
-
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
-
Valneva Announces Settlement Agreement with the UK Government
-
Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001
-
Valneva Joins Euronext’s Tech Leaders Index
-
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8
-
Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference
-
Valneva Announces the Availability of Documentation for its Shareholder Meetings
Back to VLA Stock Lookup
